Global Sexually Transmitted Diseases (STDs) Drugs: Overview
Sexually transmitted diseases (STDs), also referred as venereal
diseases are infections that can pass from person to person during
sex. These diseases are caused mainly due to bacteria, viruses, and /
or parasites. Sexually transmitted diseases (STDs) often go
undiagnosed because these infections usually do not exhibit visual
symptoms. Chlamydia is a common sexually transmitted disease. It is
caused by bacteria called Chlamydia trachomatis. It can infect both
men and women. Gonorrhea is caused due to bacterial infection
(bacterium Neisseria gonorrhoeae) that can be passed from one person
to another during sex. The human immunodeficiency virus (HIV) refers
to a type of retrovirus that causes acquired immunodeficiency
syndrome (AIDS). HIV attacks some immune cells and causes weakness of
immune system resulting in loss of ability to fight against the
organism that causes disease.
Request Sample for more Comprehensive Analysis @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34043
Global Sexually Transmitted Diseases (STDs) Drugs: Trends and
Opportunities
The global market for sexually transmitted diseases (STDs) drug is
expanding significantly, owing to increased chances of infection led
by increase in the life expectancy of people across the globe. Rise
in incidences of unprotected sex has led to an increase in the
prevalence of sexually transmitted diseases. A driving factor for the
sexually transmitted diseases (STDs) drug is rising initiatives by
governments and multiple agencies drawn up guidelines or
recommendations for sexually transmitted diseases (STDs). Low
voluntary screening rate for sexually transmitted diseases (STDs) is
major restrain for this market.
Global Sexually Transmitted Diseases (STDs) Drugs: Segmentation
The global sexually transmitted diseases (STDs) drug market has been
segmented on the basis of disease type, therapy class, distribution
channel, and region. On the bases of disease type, sexually
transmitted diseases (STDs) drug market can be further segmented into
chlamydia, gonorrhea, syphilis, human papillomavirus infection,
HIV/AIDS and others. According to therapy class sexually transmitted
diseases (STDs) drug market can be segmented into antibiotics,
antiviral, vaccines and others. Antiviral drugs are used in the
treatment of lethal viral infections caused by viruses like human
immunodeficiency virus (HIV), hepatitis, influenza A and B viruses
and herpes viruses. Vaccination has been promoted as a vital public
health intervention across the globe for decades. According to the
World Health Organization (WHO), vaccination has reduced the global
burden of infectious disease to a great extent. In terms of
distribution channel, the sexually transmitted diseases (STDs) drug
market can be segmented into hospitals pharmacies, retail pharmacies,
online pharmacies and others. In terms of revenue, the hospitals
segment held a significant share of the sexually transmitted diseases
(STDs) drug market in 2016.
Enquire for Discount @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=34043
Global Sexually Transmitted Diseases (STDs) Drugs: Regional
Outlook
Geographically, the global sexually transmitted diseases drug market
is segmented into five regions: North America, Europe, Asia Pacific,
Latin America and Middle East & Africa. These regions have been
further segmented by countries, disease type, and therapy class and
distribution channel. North America dominated the market and is
anticipated to gain more market share by the end of 2025. The
competition matrix section included in the report is likely to assist
the existing players to increase their market shares and new
companies to establish their presence in the global sexually
transmitted diseases (STDs) drug market.
Companies Mentioned in Report
The report also profiles major players in the market based on various
attributes such as company overview, financial overview, SWOT
analysis, key business strategies, product portfolio, and recent
developments. Major companies competing in the global sexually
transmitted diseases drug market, and profiled in the report include
Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson &
Johnson, Bristol-Myers Squibb Co. AbbVie, Inc., Gilead Sciences,
GlaxoSmithKline Plc, and Merck & Co., Inc.
Request TOC of the Report for Complete Review @
https://www.transparencymarketresearch.com/report-toc/34043
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment